Sphera Funds Management LTD. lifted its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 18.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 168,100 shares of the biopharmaceutical company’s stock after purchasing an additional 26,400 shares during the period. Alexion Pharmaceuticals accounts for 1.8% of Sphera Funds Management LTD.’s portfolio, making the stock its 12th largest position. Sphera Funds Management LTD. owned 0.08% of Alexion Pharmaceuticals worth $16,366,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently modified their holdings of ALXN. Captrust Financial Advisors acquired a new stake in Alexion Pharmaceuticals during the 4th quarter worth $31,000. NuWave Investment Management LLC lifted its position in shares of Alexion Pharmaceuticals by 851.9% during the fourth quarter. NuWave Investment Management LLC now owns 514 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 460 shares in the last quarter. Benjamin F. Edwards & Company Inc. bought a new position in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $68,000. We Are One Seven LLC bought a new position in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $79,000. Finally, Shine Investment Advisory Services Inc. lifted its position in shares of Alexion Pharmaceuticals by 114.1% during the fourth quarter. Shine Investment Advisory Services Inc. now owns 897 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 478 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.
In other news, CEO Ludwig Hantson sold 3,244 shares of the stock in a transaction that occurred on Monday, December 31st. The shares were sold at an average price of $95.85, for a total value of $310,937.40. Following the transaction, the chief executive officer now owns 150,696 shares in the company, valued at approximately $14,444,211.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Daniel Bazarko sold 2,000 shares of the stock in a transaction that occurred on Thursday, February 14th. The stock was sold at an average price of $126.00, for a total transaction of $252,000.00. Following the completion of the transaction, the chief accounting officer now owns 5,020 shares in the company, valued at approximately $632,520. The disclosure for this sale can be found here. Insiders have sold a total of 8,488 shares of company stock worth $873,875 in the last 90 days. Company insiders own 4.35% of the company’s stock.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $2.14 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.60 by $0.54. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.06 billion. Alexion Pharmaceuticals had a net margin of 1.88% and a return on equity of 18.15%. The company’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.48 EPS. As a group, equities research analysts predict that Alexion Pharmaceuticals, Inc. will post 8.51 earnings per share for the current year.
Several equities analysts have recently weighed in on the stock. Cowen reiterated a “buy” rating and issued a $165.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday. BidaskClub downgraded shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 7th. Guggenheim assumed coverage on shares of Alexion Pharmaceuticals in a research note on Friday, February 22nd. They issued a “neutral” rating and a $135.00 target price for the company. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, February 12th. Finally, Morgan Stanley lifted their target price on shares of Alexion Pharmaceuticals from $165.00 to $175.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 12th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $160.75.
ILLEGAL ACTIVITY NOTICE: “Sphera Funds Management LTD. Raises Position in Alexion Pharmaceuticals, Inc. (ALXN)” was originally reported by Week Herald and is the property of of Week Herald. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://weekherald.com/2019/03/14/sphera-funds-management-ltd-raises-position-in-alexion-pharmaceuticals-inc-alxn.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Story: What is a Reverse Stock Split?
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.